Clinical Trial Update: Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) [Phase 3]

View source ↗

Summary

Phase 3 trial updates evaluate upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis, with results posted in February 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2022-02-03